Lupin Expands Respiratory Portfolio with Luforbec Launch in Spain

Global pharmaceutical major Lupin Limited has officially expanded its European respiratory footprint through a new partnership with the Spanish firm Laboratorios ERN. The collaboration focuses on the launch of Luforbec® (beclometasone/formoterol), a pressurized metered-dose inhaler (pMDI) designed for the treatment of adult asthma and severe chronic obstructive pulmonary disease (COPD).

This launch follows the successful introduction of the Luforbec® brand in the United Kingdom and Germany, where it has been recognized for offering a cost-effective alternative for patients requiring a combination of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) therapy.

Enhancing Access to Respiratory Care

Luforbec® is indicated for the regular treatment of asthma in patients where the use of an ICS/LABA combination is appropriate, including those who are not adequately controlled with ICS and "as needed" short-acting bronchodilators. Furthermore, the medication is indicated for the symptomatic treatment of patients with severe COPD and a history of repeated exacerbations who continue to experience symptoms despite regular therapy with long-acting bronchodilators.

By partnering with Laboratorios ERN, a company with established local expertise in Spain, Lupin aims to streamline the distribution and adoption of this therapy among healthcare professionals and patients across the region.

A Proven Track Record in Europe

The Luforbec® inhaler has gained significant traction in other European markets due to its clinical profile and the company's commitment to sustainability. In previous launches, Lupin has emphasized that Luforbec® provides clinical equivalence to reference products while delivering significant cost savings for public health systems.

"The launch of Luforbec® represents a significant milestone in our goal to establish ourselves as a key player in the inhalation segment," stated Anjan Selz, Managing Director of Lupin’s German subsidiary, during a previous regional expansion. The Spanish launch mirrors this strategic focus on improving healthcare outcomes by ensuring the accessibility and affordability of reliable respiratory solutions.

Official Sources

• Information regarding the therapeutic indications for Luforbec® (beclometasone/formoterol) is based on the Summary of Product Characteristics (SmPC) provided by Lupin Healthcare.

• Clinical and commercial background for the Luforbec® range has been corroborated by press releases from Lupin Limited regarding its European market strategy.

Why It Matters

Respiratory conditions like asthma and COPD affect millions of individuals across Europe. The entry of Luforbec® into the Spanish market offers a new treatment option that combines therapeutic efficacy with the potential for health system cost efficiencies. This expansion reinforces Lupin’s focus on the respiratory space as a core pillar of its international growth strategy.

Key Facts at a Glance

• Product: Luforbec® (beclometasone 100mcg/formoterol 6mcg).

• Indications: Adult asthma and severe COPD with a history of exacerbations.

• Strategic Partner: Laboratorios ERN (Spain).

• Therapeutic Class: ICS/LABA combination therapy for respiratory management.

FAQ Section

Q: What is Luforbec® indicated for?

A: Luforbec® is indicated for the regular treatment of adult asthma where a combination of ICS/LABA is suitable, and for the symptomatic treatment of patients with severe COPD.

Q: How does Luforbec® function?

A: It combines beclometasone, a corticosteroid that reduces inflammation in the lungs, and formoterol, a long-acting bronchodilator that relaxes airway muscles.

Q: Who is Lupin collaborating with in Spain?

A: Lupin is collaborating with Laboratorios ERN to manage the introduction and distribution of the product in the Spanish market.

Source: Lupin Limited, Lupin Healthcare UK, Medicines.org.uk (SmPC)